Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

The labelling puts it in direct contention with Pfizer's blockbuster Vyndamax/Vyndaqel/Vynmac franchise – based on tafamidis – which has been approved for ATTR-CM since 2019 and is also used ...

The progressive and fatal ATTR-CM results from accumulation of wild ... Mycardium, Novo Nordisk, Pfizer, and Prothena. Kramer disclosed no relationships with industry.

Pfizer's Vyndaqel earned $5.5 billion in sales ... "While management prudently managed expectations — reiterating that ATTR-CM launch will be a 2H25 story — elevated long-term Street ...

Last week, the agency signed off on Alnylam’s Amvuttra to treat transthyretin amyloid cardiomyopathy (ATTR-CM) patients ... Novo Nordisk’s Alhemo and Pfizer’s Hympavzi.

The distinct proteomic profiles they identified suggest that patients with hereditary ATTR-CM may respond better to targeted therapy ... may have worse outcomes but also respond better to Pfizer ...

With new treatments being approved for ATTR-CM, there has been increased interest in improving screening for the condition. Before Attruby was approved last year, the US Food and Drug Administration ...